Tomas Ohlsson

Skåne University Hospital — Sweden

Medicine · Health Sciences

32h-index4.9kcitations129works1.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Radiopharmaceutical Chemistry and Applications(41), Medical Imaging Techniques and Applications(34), Alzheimer's disease research and treatments(20), Dementia and Cognitive Impairment Research(19), Monoclonal and Polyclonal Antibodies Research(13)

Publications128 total

Evaluation of a Sensitive Visual Read Algorithm for Assessing 3R/4R Tau PET Images
Journal of Nuclear Medicine·2025Open Access
CSF markers of neuroinflammation, synaptic dysfunction and [18F]DOPA-PET in Parkinson's disease
Parkinsonism & Related Disorders·2025· 2 citedOpen Access
Update on [18F]ACI‐12589: a novel and promising PET tracer for a‐synuclein
Alzheimer s & Dementia·2023Open Access
A prospective study evaluating the clinical utility of tau‐PET in the diagnostic work‐up of patients with cognitive symptoms
Alzheimer s & Dementia·2023Open Access
The α-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases
Nature Communications·2023· 124 citedOpen Access
Clinical Utility of Tau Positron Emission Tomography in the Diagnostic Workup of Patients With Cognitive Symptoms
JAMA Neurology·2023· 29 citedOpen Access
Additional file 1 of Relationships between uptake of [68Ga]Ga-DOTA-TATE and absorbed dose in [177Lu]Lu-DOTA-TATE therapy
Figshare·2023Open Access
Relationships between uptake of [68Ga]Ga-DOTA-TATE and absorbed dose in [177Lu]Lu-DOTA-TATE therapy
EJNMMI Research·2022· 29 citedOpen Access
[18F]RO948 tau positron emission tomography in genetic and sporadic frontotemporal dementia syndromes
European Journal of Nuclear Medicine and Molecular Imaging·2022· 9 citedOpen Access
Initial clinical scans using [<sup>18</sup>F]ACI‐12589, a novel α‐synuclein PET‐tracer
Alzheimer s & Dementia·2022· 11 cited
Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline
Nature Medicine·2022· 446 citedOpen Access
Correction to: Quantitative analysis of phantom studies of 111In and 68Ga imaging of neuroendocrine tumours
EJNMMI Physics·2022Open Access
A prospective phase II study of prostate-specific antigen-guided salvage radiotherapy and 68Ga-PSMA-PET for biochemical relapse after radical prostatectomy – The PROPER 1 trial
Clinical and Translational Radiation Oncology·2022· 7 citedOpen Access
Amyloid and Tau PET positive cognitively unimpaired individuals: Destined to decline?
2022· 7 citedOpen Access
Optimizing the reaction conditions for the GMP production of [18F]ACI-12589, a promising candidate in the development as a PET tracer targeting α-synuclein
Nuclear Medicine and Biology·2022
Optimized QMA-elution enables direct aliphatic 18F-fluorination of highly reactive tetrazines for pretargeted imaging
Nuclear Medicine and Biology·2022
Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease
JAMA Neurology·2021· 140 citedOpen Access
Biomarker driven enrichment strategies for tau pathology in AD clinical trials
Alzheimer s & Dementia·2021
Impact of reduced injected dose on the quantification of [<sup>18</sup>F]RO948 and [<sup>18</sup>F]Flortaucipir PET for <i>in vivo</i> tau pathology
Alzheimer s & Dementia·2021· 1 citedOpen Access
Insights into Elution of Anion Exchange Cartridges: Opening the Path toward Aliphatic <sup>18</sup> F-Radiolabeling of Base-Sensitive Tracers
ACS Pharmacology & Translational Science·2021· 33 citedOpen Access
page 1 of 7Next →

Frequent Co-authors

Ruben Smith(16), Oskar Hansson(16), Jonas Jögi(13), Olof Strandberg(10), Michael Schöll(9), Sebastian Palmqvist(9), Sven‐Erik Strand(8), Rik Ossenkoppele(7), Niklas Mattsson(7), Erik Stomrud(6), Elisabeth Kjellén(6), Jan Tennvall(6), Eva Brun(5), Douglas Hägerström(5), Per Olov Risman(5), A. Sandell(4), Cécilia Hindorf(4), Maria Bjurberg(4), Philip S. Insel(3), Antoine Leuzy(3)